Abstract

Vulvovaginal atrophy (VVA) is a common manifestation of menopause that significantly impairs women’s quality of life. Conventional hormone therapy, although effective, has several limitations, emphasizing the need for alternative treatment modalities. The aim of this study was to evaluate the efficacy and safety of the fractional Nd:YAG laser Magic Gyno in alleviating symptoms of VVA and genitourinary syndrome of menopause (GSM).

A retrospective and prospective study included 45 women aged 40–70 years (mean age 48.1 ± 4.71 years). The most frequent complaints were vaginal dryness (65.8%), vulvovaginal itching and burning (62.4%), dyspareunia (51.7%), postcoital spotting (9.4%), and stress urinary incontinence (20.6%). Symptom assessment was performed using the King’s Health Questionnaire (KHQ) and the Barlow scale.

The Magic Gyno Nd:YAG laser (1064 nm) provides a physiological and targeted effect on collagen, elastin, and hemoglobin, enhancing tissue hydration and epithelialization at a depth of 3–4 mm. The procedure was conducted in two stages under aseptic conditions using conical and angled probes in G-scanner mode. After the first session, 65% of patients reported improvement according to KHQ results; by the end of the treatment course, 89% showed complete resolution of clinical and visual signs of atrophy, while 11% required a repeat session within 4–6 weeks.

Side effects were minimal and transient—mild edema and erythema in 12% of cases during the first 48 hours, which resolved spontaneously. No infections, scarring, or worsening of symptoms were reported. The overall satisfaction rate reached 94.7%.

Laser therapy demonstrated high efficacy and safety, providing a long-lasting improvement in mucosal quality and symptom relief for up to 3 months after treatment. Based on the results, it is recommended to repeat the course after 2 months to maintain the therapeutic effect.

The fractional Nd:YAG laser Magic Gyno represents a promising non-hormonal alternative for the management of VVA and GSM in outpatient gynecological practice, particularly for patients with contraindications to hormone therapy. Further research is required to assess long-term outcomes and optimize treatment protocols.